Clinical trials: Tumor Patients
Prostatic Neoplasms
Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer
To compare the efficacy of both strategies (reference treatment: Docetaxel+Prednisone and experimental treatment: Docetaxel+Estramustine+Hydrocortisone) by means of PSA values.
- Trial name
- PROSTATA (NCT00705822)
- Testing
- Docetaxel + Estramustine + Hydrocortisone, Docetaxel + Prednisone
- Where
- Spain
- Volunteers
- 54 people
- Sponsor
- Sanofi
Barrett Esophagus
HALO Patient Registry: Ablation of Barrett's Esophagus
The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD).
- Trial name
- NCT00848237
- Testing
- Radiofrequency Ablation (HALO Ablation Systems)
- Where
- United States
- Volunteers
- 5,521 people
- Sponsor
- Medtronic - MITG
Breast Neoplasms, Neoplasm Metastasis
A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
The goal of this phase 1 open label clinical trial is to evaluate the safety and preliminary efficacy of CodaLytic, an intratumorally-administered oncolytic virus, in patients with metastatic or otherwise inoperable breast…
- Trial name
- NCT05600582
- Testing
- CodaLytic
- Where
- 2 sites in United States
- Sponsor
- Codagenix, Inc
Advanced Solid Tumors
A Study of BGM-2121 in Patients With Advanced Solid Tumors
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
- Trial name
- NCT07346846
- Testing
- BGM-2121
- Where
- 3 sites in Taiwan
- Volunteers
- 35 people
- Sponsor
- BioGate Precision Medicine Corp.
Hematological Malignancies
Safety and Efficacy of SMART101 in Pediatric and Adult Patients With Hematological Malignancies After T Cell Depleted Allo-HSCT
The purpose of this study is to evaluate the safety and the efficacy of SMART101 (Human T Lymphoid Progenitor (HTLP)) injection to accelerate immune reconstitution after T cell depleted allogeneic hematopoietic stem cell…
- Trial name
- NCT04959903
- Testing
- Allogeneic T cell progenitors, cultured ex-vivo
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Smart Immune SAS
Small-cell Lung Cancer, Neuroendocrine Carcinomas
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
This is Phase 1/2, multicenter, clinical study to evaluate the safety, efficacy, PK, and immunogenicity of IDE849 in subjects with DLL3-expressing tumors including SCLC.
- Conditions
- Small-cell Lung Cancer, Neuroendocrine Carcinomas, Solid Tumor Show to Express DLL3
- Trial name
- NCT07174583
- Testing
- IDE849, durvalumab, IDE161
- Where
- 13 sites in United States
- Volunteers
- 262 people
- Sponsor
- IDEAYA Biosciences
Cancer, Malignant Tumors
A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD) of E7974 administered on Days 1 and 15 of a 28-day cycle in subjects with solid malignancies that have progressed following effective therapy or for which…
- Trial name
- NCT00130169
- Testing
- E7974
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Pulmonary Diseases, Neoplasms, Lung
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
This study evaluated the efficacy and safety of aflibercept in the treatment of participants with advanced chemoresistant non-small cell lung adenocarcinoma (NSCLA).
- Trial name
- NCT00284141
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 3 sites in United States, Canada and 1 more
- Volunteers
- 98 people
- Sponsor
- Sanofi
Pancreatic Cancer
Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug or giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00004861
- Testing
- gemcitabine hydrochloride, tacedinaline
- Where
- 16 sites in United States, Canada
- Sponsor
- Pfizer
Effectiveness，Safety，Thymic Cancer
A Phase 2 Clinical Study of YY-20394 in Patients With Relapsed/Refractory Thymic Cancer
This study is a single-arm, open, multi-center phase II clinical trial, the main purpose of which is to evaluate the effectiveness and safety of YY-20394 in the treatment of patients with relapsed/refractory thymic cancer.
- Trial name
- NCT04975061
- Testing
- YY-20394
- Volunteers
- 58 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Cancer (Solid Tumors)
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
The purpose of this clinical research is to assess the safety and tolerability of BMS-690514 when given in combination with paclitaxel and carboplatin.
- Trial name
- NCT00420186
- Testing
- BMS-690514
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 37 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the…
- Trial name
- FLAURA2 (NCT04035486)
- Testing
- Osimertinib, Pemetrexed/Carboplatin, Pemetrexed/Cisplatin
- Where
- 153 sites in United States, Argentina and 19 more
- Volunteers
- 587 people
- Sponsor
- AstraZeneca
Leukemia, Lymphoblastic, Acute, Pediatric
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Trial name
- NCT00042341
- Testing
- clofarabine (IV formulation)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Superficial Bladder Cancer
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder cancer.
- Trial name
- NCT02007005
- Testing
- abnobaVISCUM Fraxini
- Where
- 2 sites in Egypt, Germany
- Volunteers
- 37 people
- Sponsor
- Abnoba Gmbh
Advanced or Metastatic Solid Tumors
A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors
To investigate the safety and efficacy of nivolumab as a single agent or in combination with ipilimumab in 6 tumor types - triple-negative breast cancer (TNBC), gastric cancer (GC), pancreatic adenocarcinoma (PC), small cell lung…
- Trial name
- NCT01928394
- Testing
- Nivolumab, Ipilimumab, Cobimetinib
- Where
- 38 sites in United States, Canada and 6 more
- Volunteers
- 1,163 people
- Sponsor
- Bristol-Myers Squibb
Hodgkin Disease
A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma
The purpose of this study is to assess the safety, tolerability, and anti-tumor activity, as well as confirm the recommended dose of brentuximab vedotin (ADCETRIS) in combination with a multiagent chemotherapy regimen…
- Trial name
- NCT02979522
- Testing
- Brentuximab vedotin, Doxorubicin, Vinblastine
- Where
- 14 sites in United States, Brazil and 2 more
- Volunteers
- 59 people
- Sponsor
- Takeda
Hematologic Malignancy
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
This is an open, multi-cohort clinical study. The first phase is a dose escalation study and the second phase is a dose expansion study based on the Maximum tolerated dose (MTD) / Recommended Phase II Dose (RP2D) obtained in the…
- Trial name
- NCT06211751
- Testing
- TQB3909 tablets, TQB3702 tablets
- Where
- China
- Volunteers
- 208 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Actinic Keratosis
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.
- Trial name
- NCT00375739
- Testing
- PEP005
- Where
- 24 sites in United States
- Volunteers
- 200 people
- Sponsor
- Peplin
Breast Neoplasms, Prostatic Neoplasms
Study to Investigate Adherence of Patients to Clodronate (Bonefos) Treatment
Adherence (or compliance with) a medication regimen is generally defined as the extent to which patients take medication as prescribed by their health care providers.
- Conditions
- Breast Neoplasms, Prostatic Neoplasms, Multiple Myeloma, Osteolysis
- Trial name
- BONA (NCT01198457)
- Testing
- Clodronate (Bonefos, BAY94-8393)
- Where
- Czechia
- Volunteers
- 147 people
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.